Dr. Muredach P. Reilly received his medical degree from University College Dublin, Ireland and completed his residency and fellowship training in Medicine and Cardiovascular Medicine at the University of Pennsylvania, where he also received a M.S. degree in clinical and genetic epidemiology.
Dr. Reilly is the Herbert and Florence Irving Professor of Medicine and Vice Dean for Clinical and Translational Research at Columbia University Irving Medical Center in New York, USA. He is Director of the Irving Institute for Clinical and Translational Research, and PI of Columbia University’s NIH funded Clinical and Translational Science Award (CTSA) Program hub. He is also a Vice Dean for Research at the Vagelos College of Physicians and Surgeon at Columbia University, New York, USA.
Dr. Reilly serves as the Director of the Cardiometabolic Precision Medicine Program in the
Division of Cardiology at Columbia University. His research program is dedicated to translational precision medicine studies of human atherosclerosis and heart disease as well as inflammatory mechanisms in cardio-metabolic disease, emphasizing humans as the most ideal “model” to understand mechanisms of and therapeutic opportunities for human disease and prevention.

Professor Marianne Benn, MD, PhD and DMSc is senior consultant at Department of Clinical Biochemistry, Rigshospitalet, Copenhagen; professor in Clinical Biochemistry with special focus on Translational Medicine; and co-chair of the BRIDGE – Translational Excellence Programme at University of Copenhagen, Denmark.
Her main research interest is genetic epidemiology using Mendelian randomization designs to examine the unconfounded effects of environmental factors and biological markers on risk of cardiovascular disease in the general population, for prediction of unintended effects of drugs, and examining the contributions and mechanisms of risk factors such as obesity, LDL cholesterol, diabetes to micro- and macrovascular disease. Professor Benn will join us online via Zoom (in collaboration with the European Atherosclerosis Society).

Dr. Jong-Chan Youn is a Professor at the Division of Cardiology, Seoul St. Mary’s Hospital, The Catholic University of Korea. After graduating from Yonsei University College of Medicine, he obtained his Ph.D. from the same institution. He then worked as a full-time postdoctoral researcher at KAIST’s Immunology Lab, where he focused on cardiovascular immunology and senescent T cell research. Dr. Youn has published a series of articles on senescent T cells and their impact on human hypertension, arterial stiffening, myocardial infarction, and heart failure. His clinical expertise encompasses hypertension, dyslipidemia, and heart failure. Dr Youn’s conference attendance is partially supported by Korean Society of Lipids and Atherosclerosis (KSoLA).


Professor Kerry-Anne Rye (BSc (Hons), PhD, FAHA) is Deputy Head of the School of Biomedical Sciences and Head of the Cardiometabolic Research Group in the Faculty of Medicine at UNSW Sydney. She is the Immediate Past-Chair of the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Council Nominations Committee, Editor-in-Chief of the Journal of Lipid Research and Senior Editor of the Journal of the American Heart Association. Professor Rye is recognised internationally for her work on high density lipoprotein (HDL) structure and function and cardiometabolic disease. She has published over 300 peer-reviewed papers on these topics in discipline-specific and general journals. Her current research focus is on the development of novel, therapies for treatment of diabetes-accelerated atherosclerosis.

Associate Professor Peter Psaltis (MBBS (Hons), PhD, FRACP, FCSANZ, FESC) is an academic interventional cardiologist and vascular biologist, who holds Faculty positions at SAHMRI, CALHN and the University of Adelaide. He is the Deputy Director of SAHMRI, co-leads its largest research department, the Lifelong Health Theme of more >350 researchers, and leads its Heart and Vascular Program. Concurrently, he is also Head of Interventional Coronary Services in the Department of Cardiology, Royal Adelaide Hospital.
Peter has expertise across all three disciplines of basic, translational, and clinical research and leads bench-to-bedside projects spanning topics of developmental macrophage biology, vascular stem cells, inflammatory regulation of atherosclerosis, pharmacological modification of atherosclerosis, coronary plaque imaging, the modelling of biomechanical forces in coronary arteries and cardiometabolic disease.